Fujifilm announced on December 20 that their subsidiary Fujifilm Cellular Dynamics will invest about 2.5 billion Yen (~20 million €) in Madison, Wisconsin.  Targets are regenerative medical products in the area of ​​age-related macular degeneration, retinal pigment degeneration, Parkinson’s disease, heart disease and cancer using high-quality iPS cells produced at this facility from 2019 on.

Fujifilm news release, December 20, 2018